Annual Drug Patent Expirations for BYDUREON Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are thirty patents…
The post Patent delisted for Astrazeneca Ab drug BYDUREON appeared first…
Patent delisted for Astrazeneca Ab drug BYDUREON Read Post »
DEXYCU KIT (dexamethasone) Eyepoint pharms Patent: 10,022,502 Expiration: Sep 12, 2020 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected]…
The post Dru…
Drug Patent Expirations for the Week of September 6, 2020 Read Post »
Annual Drug Patent Expirations for LONSURF Lonsurf is a drug marketed by Taiho Oncology and is included in one NDA. It is available from one supplier. There are five patents…
The post Patent delisted for Taiho Oncology drug LONSURF appeared first on Dr…
Annual Drug Patent Expirations for PREVYMIS Prevymis is a drug marketed by Merck Sharp Dohme and is included in two NDAs. It is available from one supplier. There are three…
The post Patent delisted for Merck Sharp drug PREVYMIS appeared first on DrugP…
Annual Drug Patent Expirations for TRIJARDY+XR Trijardy Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are fifteen…
The post Patent delisted for Boehringer Ingelheim drug TRIJARDY XR a…
Patent delisted for Boehringer Ingelheim drug TRIJARDY XR Read Post »
Annual Drug Patent Expirations for OFEV Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five patents…
The post Patent delisted for Boehringer Ingelheim drug OFEV appeared first on…
Patent delisted for Boehringer Ingelheim drug OFEV Read Post »
Annual Drug Patent Expirations for GLYXAMBI Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from two suppliers. There are eleven patents…
The post Patent delisted for Boehringer Ingelheim drug GLYXAMBI ap…
Patent delisted for Boehringer Ingelheim drug GLYXAMBI Read Post »
Annual Drug Patent Expirations for ENVARSUS+XR Envarsus Xr is a drug marketed by Veloxis Pharms Inc and is included in one NDA. It is available from one supplier. There are…
The post Patent delisted for Veloxis Pharms drug ENVARSUS XR appeared first on…
Patent delisted for Veloxis Pharms drug ENVARSUS XR Read Post »
Annual Drug Patent Expirations for ABILIFY+MYCITE+KIT Abilify Mycite Kit is a drug marketed by Otsuka and is included in one NDA. It is available from one supplier. There are thirty-one…
The post Patent delisted for Otsuka drug ABILIFY MYCITE KIT appea…
Patent delisted for Otsuka drug ABILIFY MYCITE KIT Read Post »
Annual Drug Patent Expirations for TRADJENTA Tradjenta is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from three suppliers. There are nine patents…
The post Patent delisted for Boehringer Ingelheim drug TRADJENTA…
Patent delisted for Boehringer Ingelheim drug TRADJENTA Read Post »